Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890126575> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2890126575 abstract "5592 Background: mEC is a generally incurable, with limited therapeutic options. ONC201 is the founding member of the new class of compounds called imipridones that are orally active small molecules. ONC201 a specific antagonist of the G protein-coupled receptor DRD2 exerts antitumor activity via a series of established signaling pathways (dual inhibition ERK/AKT, integrated stress response). DRD2 expression is elevated in malignant versus normal endometrial tissue. Furthermore ONC201 has shown anti-cancer activity in preclinical models of EC. Methods: In a Phase I trial that included an expansion cohort, a total of 28 evaluable patients (pts) were treated with ONC201 at doses from 125mg every 3 weeks to 625 weekly. Five of these patients had advanced mEC. Results: The median age for the mEC patients was 60 years (56-72), the median number of prior treatments was 5 (3-6), 3 patients had prior radiation and all patients had prior surgery. One patient received 375mg ONC201 while the other 4 patients received 625mg ONC201, orally every 3 weeks. The median number of doses was 3 (2-14). Two of 5 patients exhibited regressions in individual metastatic lesions, however they did not qualify as overall objective responses by RECIST criteria. One of these two patients experienced stable disease for 42 weeks. There were no reported SAEs and no Grade > 1 AEs attributed to study drug. Conclusions: ONC201 is clinically active and well tolerated with oral administration in refractory mEC patients. Clinical trial information: NCT02250781. [Table: see text]" @default.
- W2890126575 created "2018-09-27" @default.
- W2890126575 creator A5008547275 @default.
- W2890126575 creator A5012047866 @default.
- W2890126575 creator A5021933787 @default.
- W2890126575 creator A5024832960 @default.
- W2890126575 creator A5030899790 @default.
- W2890126575 creator A5036916387 @default.
- W2890126575 creator A5041474007 @default.
- W2890126575 creator A5045679809 @default.
- W2890126575 creator A5047699205 @default.
- W2890126575 creator A5048331793 @default.
- W2890126575 creator A5053602981 @default.
- W2890126575 creator A5054371540 @default.
- W2890126575 creator A5055837818 @default.
- W2890126575 creator A5063899863 @default.
- W2890126575 creator A5071773606 @default.
- W2890126575 creator A5081735541 @default.
- W2890126575 creator A5089654215 @default.
- W2890126575 date "2017-05-20" @default.
- W2890126575 modified "2023-09-28" @default.
- W2890126575 title "Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC)." @default.
- W2890126575 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.5592" @default.
- W2890126575 hasPublicationYear "2017" @default.
- W2890126575 type Work @default.
- W2890126575 sameAs 2890126575 @default.
- W2890126575 citedByCount "1" @default.
- W2890126575 countsByYear W28901265752020 @default.
- W2890126575 crossrefType "journal-article" @default.
- W2890126575 hasAuthorship W2890126575A5008547275 @default.
- W2890126575 hasAuthorship W2890126575A5012047866 @default.
- W2890126575 hasAuthorship W2890126575A5021933787 @default.
- W2890126575 hasAuthorship W2890126575A5024832960 @default.
- W2890126575 hasAuthorship W2890126575A5030899790 @default.
- W2890126575 hasAuthorship W2890126575A5036916387 @default.
- W2890126575 hasAuthorship W2890126575A5041474007 @default.
- W2890126575 hasAuthorship W2890126575A5045679809 @default.
- W2890126575 hasAuthorship W2890126575A5047699205 @default.
- W2890126575 hasAuthorship W2890126575A5048331793 @default.
- W2890126575 hasAuthorship W2890126575A5053602981 @default.
- W2890126575 hasAuthorship W2890126575A5054371540 @default.
- W2890126575 hasAuthorship W2890126575A5055837818 @default.
- W2890126575 hasAuthorship W2890126575A5063899863 @default.
- W2890126575 hasAuthorship W2890126575A5071773606 @default.
- W2890126575 hasAuthorship W2890126575A5081735541 @default.
- W2890126575 hasAuthorship W2890126575A5089654215 @default.
- W2890126575 hasConcept C121608353 @default.
- W2890126575 hasConcept C126322002 @default.
- W2890126575 hasConcept C143998085 @default.
- W2890126575 hasConcept C170493617 @default.
- W2890126575 hasConcept C2776885963 @default.
- W2890126575 hasConcept C2777088508 @default.
- W2890126575 hasConcept C71924100 @default.
- W2890126575 hasConcept C98274493 @default.
- W2890126575 hasConceptScore W2890126575C121608353 @default.
- W2890126575 hasConceptScore W2890126575C126322002 @default.
- W2890126575 hasConceptScore W2890126575C143998085 @default.
- W2890126575 hasConceptScore W2890126575C170493617 @default.
- W2890126575 hasConceptScore W2890126575C2776885963 @default.
- W2890126575 hasConceptScore W2890126575C2777088508 @default.
- W2890126575 hasConceptScore W2890126575C71924100 @default.
- W2890126575 hasConceptScore W2890126575C98274493 @default.
- W2890126575 hasLocation W28901265751 @default.
- W2890126575 hasOpenAccess W2890126575 @default.
- W2890126575 hasPrimaryLocation W28901265751 @default.
- W2890126575 hasRelatedWork W1547515123 @default.
- W2890126575 hasRelatedWork W3022624188 @default.
- W2890126575 isParatext "false" @default.
- W2890126575 isRetracted "false" @default.
- W2890126575 magId "2890126575" @default.
- W2890126575 workType "article" @default.